Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
85 participants
INTERVENTIONAL
2006-07-31
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Interventions : During 4 months the intervention group received 2.5 gr of magnesium chloride (50 ml of a solution containing 50 gr of MgCl2 by 1000 ml of solution ). Controls received inert placebo.
Main outcome measure: Change in blood pressure. Increase of serum magnesium Secondary outcomes measures: Changes in lipid profile
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Magnesium chloride
Magnesium chloride
Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
2
Placebo
Placebo
Subjects in the control group received inert placebo once per day during 4 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Magnesium chloride
Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
Placebo
Subjects in the control group received inert placebo once per day during 4 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Decreased serum magnesium levels
* Uncomplicated hypertension
* 40 and 75 years of age
* Men and Women
Exclusion Criteria
* Alcohol intake (equal or more than 30 g per day)
* Use of diuretics and/or calcium antagonists drugs
* Previous oral magnesium supplementation
* Ischemic diseases; AND
* Reduced renal function
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Mexicano del Seguro Social
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Biomedical Research Unit, Instituto Mexicano del Seguro Social
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martha Rodriguez-Moran, MD, MSc, PhD
Role: PRINCIPAL_INVESTIGATOR
Instituto Mexicano del Seguro Social
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biomedical Research Unit
Durango, Durango, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IMSS
Identifier Type: -
Identifier Source: secondary_id
2000-161-0027
Identifier Type: -
Identifier Source: org_study_id